menu
    • menu
    [{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Lassen Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Lassen Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Lassen Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lassen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lassen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Cedars-Sinai","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Lassen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Lassen Therapeutics"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Frazier Healthcare Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Lassen Therapeutics

    Menu

    Lassen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

                            Details : LASN01 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graves Ophthalmopathy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 26, 2024

                            Lead Product(s) : LASN01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Frazier Life Sciences

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Pat...

                            Details : The net proceeds from will support the LASN01, a first-in-class monoclonal antibody targeting the receptor for IL-11, clinical program and advance IND-enabling activities for LASN500, a highly potent, first-in-class monoclonal antibody targeting the IL-1...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : LASN01

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Frazier Life Sciences

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach f...

                            Details : LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R), is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic approaches.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Rece...

                            Details : In vitro assays demonstrated potent blockade of IL-11-stimulated signaling by LASN01 and inhibition of TGF-β-stimulated collagen expression by patient-derived IPF fibroblasts. In ex vivo assays using normal human lung tissue.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 17, 2022

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subj...

                            Details : LASN01 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 15, 2022

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Recipient : Cedars-Sinai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lassen Therapeutics Collaborates with Cedars Sinai to Study the Role of IL-11 Signaling and Inhibition in Lung...

                            Details : The collaboration will study the role of IL-11 signaling and its inhibition in lung fibrosis, particularly idiopathic pulmonary fibrosis, and the potential therapeutic effect of monoclonal antibodies, which includes LASN01, that block this signaling in p...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : LASN01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Recipient : Cedars-Sinai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lassen Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LASN01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Frazier Healthcare Partners

                            Deal Size : $31.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics to Treat Fibrosis and Oncolog...

                            Details : Proceeds from the financing to be used to develop antibodies as potential treatments for fibrosis. Lassen Therapeutics is developing LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor alpha (IL-11R).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 17, 2020

                            Lead Product(s) : LASN01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Frazier Healthcare Partners

                            Deal Size : $31.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth